Previous 10 | Next 10 |
Therapeutic Solutions International (OTCPK:TSOI) said it was issued U.S. Patent #11,266,707 titled, Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19. The company said the patent covers composition of matter and uses of QuadraMune to preve...
Commercially Available Nutraceutical with Established Immunomodulatory Activities is Protected by Issuance of Composition of Matter and Mechanism of Action Claims Therapeutic Solutions International announced today issuance of United States Patent #11,266,707 entitled ȁ...
Research Findings Associated with Company’s COVID-19 Program Yield Potentially Paradigm Shifting Intellectual Property Therapeutic Solutions International announced today data on what the Company believes to be a novel procedure to enhance anti-inflammatory and regene...
Suicide Prevention Company Leverages Cell Therapy Expertise of Therapeutic Solutions International and Allogen Biologics to Advance First Cell Therapy Product Towards Clinical Trials Therapeutic Solutions International announced today positive preclinical efficacy and safety...
New Data Suggests Possible Efficacy of QuadraMune ® in Treatment of COVID-19 “Brain Fog” Therapeutic Solutions International announced today filing of a new patent covering data demonstrating QuadraMune administration reduces cognitive decline caused b...
Clinical Study Shows 7 Day Course of QuadraMune ® Reduces COVID-19 Hyperinflammation Induced by Monocytes Therapeutic Solutions International (TSOI) announced today positive results of a pilot clinical trial in 20 subjects. In the study, ten subjects receive...
Therapeutic Solutions International's (OTCPK:TSOI) nutraceutical supplement QuadraMune received a patent related to stimulating the immune system by blocking immune suppressive activities used by cancer and viruses in the indolamine 2,3 deoxygenase (IDO) pathway. The company re...
QuadraMune ® Commercially Available “Checkpoint Inhibitor Nutraceutical” Shown to Target Immune Suppressive Indolamine 2,3 Deoxygenase Pathway Therapeutic Solutions International announced today receipt of a Notice of Allowance from the United States P...
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies PR Newswire ELK CITY, Idaho , Oct. 4, 2021...
Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing Company with Stem Cell in FDA Cleared Phase III COVID-19 Clinical Trial Comments on Scientific Su...
News, Short Squeeze, Breakout and More Instantly...
Therapeutic Sltns Intl Company Name:
TSOI Stock Symbol:
OTCMKTS Market:
Therapeutic Sltns Intl Website:
Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Tra...
Therapeutic Solutions International Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distr...
Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the abi...